SANTA ANA, Calif.--(BUSINESS WIRE)--Cold Genesys, Inc., a late-stage immuno-oncology company, today announced the appointment of two independent members to its Board of Directors: Leonard Post, Ph.D. and James Mulé, Ph.D. In addition, Paola Grandi, Ph.D., a scientific leader in the field of immuno-oncology and oncolytic vectors, has been appointed as the Chief Scientific Officer of Cold Genesys.
“We are excited to announce the addition of these scientific leaders and accomplished biotech industry leaders in the area of immuno-therapy to Cold Genesys,” said Arthur Kuan, Chief Executive Officer of Cold Genesys. “Their experience will be instrumental as we continue the development of our lead oncolytic immunotherapy compound, CG0070, in bladder cancer and across a variety of solid tumor types to be used alone or in combination therapy.”
Leonard Post, Ph.D.
Dr. Leonard Post brings more than three decades of pharmaceutical R&D experience. He is currently Chief Scientific Officer at Vivace Therapeutics. Previous experience included roles as Chief Scientific Officer of BioMarin, Chief Scientific Officer of LEAD Therapeutics, SVP of R&D at Onyx Pharmaceuticals, and positions at Parke-Davis and Upjohn. His experience with oncolytic viruses began with the adenovirus program at Onyx, and later as a member of the Boards of Directors of BioVex and then Viralytics. He is currently a member of the boards of directors at Vivace, Orphagen, Fedora, and Oxyrane. Leonard has a Ph.D. in Biochemistry and did postdoctoral work in virology, including some of the early work on genetic engineering of herpes simplex virus.
James Mulé, Ph.D.
Dr. James Mulé currently serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Scientific Director of Cell-based Therapies at the Moffitt Cancer Center. Previously, he was in Palo Alto, California, where he was involved in the birth of two startup companies while adjunct visiting faculty member in the Department of Surgery, Stanford University. He then moved to Ann Arbor, Michigan, as the Director of the Tumor Immunology and Immunotherapy Clinical Research Program at the University of Michigan Comprehensive Cancer Center.
James is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. James serves on the Advisory Boards of several NCI-designated Cancer Centers and was a member of the NCI's Board of Scientific and Clinical Counselors. He served as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, and is a Special Government Employee of the NCI and the FDA. He is on the advisory boards of numerous biotechnology and pharma companies (e.g., OncoPep, Iovance, Vault Pharma, Celgene, among others). James has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy.
Paola Grandi, Ph.D.
Dr. Paola Grandi is widely regarded as a scientific leader in the field of immuno-oncology and is responsible for directing the clinical and translational research program at Cold Genesys. Paola earned a Ph.D. in Biochemistry from the University of Ferrara (Italy) in 2001 before moving to the U.S. to pursue her interests in oncolytic Herpes Simplex Virus-based vectors for the treatment of recurrent malignant glioblastoma. After four years of post-doctoral research at the Massachusetts General Hospital in Boston, Paola joined the Departments of Neurological Surgery and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine where she developed the next-generation Oncolytic HSV-based vectors armed with novel payload combinations that altered the tumor microenvironment (TME) to promote the development of anti-tumor immunity. As an NIH funded principal investigator, she carried out pioneering work to combine the use of retargeted HSV vectors with cellular microRNA regulation of viral genes in non-tumor tissue to limit vector oncolytic activity to brain tumors. Her academic research produced several key patents that provided the core technologies to establish a start-up oncolytic vector company, Oncorus, Inc. in Cambridge, MA as company co-founder, scientific advisory board member and early stage director of company research.
About Cold Genesys
Cold Genesys is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. The company’s lead candidate CG0070 is currently under investigation in a Phase II, single-arm, open-label, multicenter study (BOND2) for patients with NMIBC who failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators in different solid tumors.